Seeking emergency use authorization for a new vaccine variant could potentially boost Novavax's market position and revenue, reflecting positively on its stock. However, the workforce reduction is a cost-cutting measure, likely due to financial pressures, which could have mixed implications for investor confidence. The net impact is considered slightly positive in the short term due to the potential for increased revenue and market share from the new vaccine, despite the underlying financial concerns.